Owlstone Medical Appoints Mark Capone to its Board

Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, has appointed Mark Capone, former president and CEO of Myriad Genetics, to its board as an independent non-executive director. Following this appointment, the Owlstone Medical Board comprises seven members including one executive director and two independent non-executive directors.
 
“We are excited to welcome Mark Capone to the Board at this important stage in our development,” said Billy Boyle, co-founder and CEO at Owlstone Medical. “Mark is a recognized leader in the diagnostics industry who’s proven track record and deep commercial and corporate experience will be instrumental as we prepare to deploy Breath Biopsy into clinical settings for applications including lung cancer and liver disease.”
 
Capone is an accomplished 35-year life sciences executive, most recently serving as president and CEO of Myriad Genetics, which he transformed from a pioneering startup to one of the largest precision medicine companies in the world. During his 17-year tenure, the company developed and launched more than a dozen reimbursed molecular diagnostics achieving total annual revenues of more than $800 million. Prior to Myriad, he spent 17-years at Eli Lilly and Company in various positions across the entire value chain.

Capone earned a bachelor of science degree in chemical engineering from Penn State University, graduating with highest distinction, and a master of science degree in biochemical engineering and master of science degree in management from Massachusetts Institute of Technology. He currently serves as president and CEO of Precision Medicine Advisors LLC, and is a non-executive board member of Abcam plc, Micoba Life Sciences Ltd., and NephroSant Inc.
 
“Owlstone Medical is poised to transform diagnostics through Breath Biopsy and I am very pleased to have been asked to help realize the vision of the team,” commented Capone. “I have been impressed with the potential of the platform, the progress made in high need clinical areas, and the passion and dedication of the leadership, and I look forward to helping drive the company’s success by supporting the development of their regulatory, reimbursement, and commercial strategy.”
 
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy. The company’s Breath Biopsy platform includes ReCIVA, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, U.K., with support through our office in Research Triangle Park, N.C., and the development of the world’s largest Digital Breath Biobank matched to patient phenotype. Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the development of Tests and RUO Panels for the early detection of disease with an emphasis on cancer, and on precision medicine initially targeting liver and respiratory disease. 
 
The Breath Biopsy OMNI (Owlstone Medical Novel Insights) Assay is Owlstone Medical’s solution for end-to-end breath sample collection and VOC analysis, which is being deployed with large pharma including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline, and leading academic institutions. Owlstone Medical’s technology is currently in use at more than 100 sites worldwide.